Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech stocks hitting 52-week highs on Feb. 20)
-
Amphastar Pharmaceuticals Inc (NASDAQ: AMPH)
-
Gossamer Bio Inc (NASDAQ: GOSS) (IPOed
on Feb. 8)
-
Intec Pharma Ltd (NASDAQ: NTEC)
-
NxStage Medical, Inc. (NASDAQ: NXTM)(received anti-trust clearance for its proposed acquisition by
Fresenius Medical Care AG & Co. (NYSE: FMS)
-
Osiris Therapeutics, Inc. (NASDAQ: OSIR)
-
PDL BioPharma Inc (NASDAQ: PDLI)
-
Synthorx Inc (NASDAQ: THOR)
Down In The Dumps
(Biotech stocks hitting 52-week lows on Feb. 20)
-
Achaogen Inc (NASDAQ: AKAO)(announced
closing of underwritten public offering of $15 million worth of shares)
-
MOTIF BIO PLC/S ADR (NASDAQ: MTFB)
-
Ovid Therapeutics Inc (NASDAQ: OVID)(announced
a concurrent offering of common stock and preferred shares)
-
Seelos Therapeutics Inc (NASDAQ: SEEL)
Stock In Focus
Genomic Health Q4 Results Beat Estimates
Genomic Health, Inc. (NASDAQ: GHDX)
reported fourth-quarter revenues of $104.6 million. Net income climbed from 5 cents per share to 23 cents per share and non-GAAP
net income increased from $2.9 million to $12.4 million. The results exceeded estimates.
For the full-year 2019, the company expects non-GAAP EPS of $1.38-$1.54 on revenues of $436 million to $448 million. The
bottom-line guidance exceeded forecast and the revenue guidance was in line.
The stock rose 3.99 percent to $72 in after-hours trading.
Hoth Completes IPO
Hoth Therapeutics Inc (NASDAQ: HOTH)
said it closed its initial public offering of 1.25 million shares at $5.60 per share, mobilizing aggregate gross proceeds of $7
million through the offering. The shares began trading on the Nasdaq Feb. 15.
Shares fell 7.47 percent to $7.31 in after-hours trading.
See Also: Intercept
Shares Soar To Multimonth High After NASH Drug Aces Late-Stage Trial
Mannkind Presents Positive Data For Its Inhaled Insulin at Diabetes Conference
MannKind Corporation (NASDAQ: MNKD)
announced additional positive Afrezza results at the 12th International Conference on Advanced Technologies & Treatments for
Diabetes.
Afreeza
is a rapidly-acting inhaled insulin used to treat Type 1 and Type 2 diabetes.
"By delivering a time-action profile closer to that of physiologic insulin action, post-prandial glucose levels and other
markers of glycemic control were significantly improved compared to injected insulin in meal-challenge tests in patients with type
2 diabetes," said David Kendall, Chief Medical Officer of MannKind.
The stock gained 2.72 percent to $1.51 in after-hours trading.
AbbVie's Humira Wins Approval For Yet Another Indication In Japan
AbbVie Inc (NYSE: ABBV) and partner Eisai
said they have received approval for an additional indication of Humira in Japan, bringing up the total approvals for the drug to
11 in Japan. This time around, the Japanese regulatory body approved Humira for hidradenitis suppurativa, a painful inflammatory
skin disease.
AbbVie
shares ended little changed at $80.01 in after-hours trading.
On The Radar
Earnings
Integra Lifesciences Holdings Corp (NASDAQ: IART) (before the market open)
Repligen Corporation (NASDAQ: RGEN)
(before the market open)
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
(after the market close)
DexCom, Inc. (NASDAQ: DXCM) (after the
market close)
Anika Therapeutics Inc (NASDAQ: ANIK)
(after the market close)
Emergent Biosolutions Inc (NYSE: EBS (after the market close)
EXACT Sciences Corporation (NASDAQ: EXAS)
(after the market close)
Nevro Corp (NYSE: NVRO)(after the market
close)
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (after the market close)
Cytokinetics, Inc. (NASDAQ: CYTK) (after
the market close)
STAAR Surgical Company (NASDAQ: STAA)
(after the market close)
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.